NASDAQ:CRNX - Crinetics Pharmaceuticals Stock Price, Forecast & News

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.57) by $0.03. The business had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.33 million. View Crinetics Pharmaceuticals' Earnings History.

Crinetics Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Crinetics Pharmaceuticals.

3 Wall Street analysts have issued 12-month price targets for Crinetics Pharmaceuticals' stock. Their forecasts range from $35.00 to $40.00. On average, they expect Crinetics Pharmaceuticals' stock price to reach $37.33 in the next year. This suggests a possible upside of 77.1% from the stock's current price. View Analyst Price Targets for Crinetics Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Crinetics Pharmaceuticals.

Media coverage about CRNX stock has trended extremely negative on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Crinetics Pharmaceuticals earned a news impact score of -4.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals saw a decline in short interest in January. As of January 15th, there was short interest totalling 1,840,000 shares, a decline of 9.8% from the December 31st total of 2,040,000 shares. Based on an average trading volume of 56,600 shares, the short-interest ratio is currently 32.5 days. Currently, 13.2% of the shares of the stock are sold short. View Crinetics Pharmaceuticals' Current Options Chain.

Some companies that are related to Crinetics Pharmaceuticals include Principia Biopharma (PRNB), Aurinia Pharmaceuticals (AUPH), Cambrex (CBM), Prestige Consumer Healthcare (PBH), Pacira Biosciences (PCRX), Karuna Therapeutics (KRTX), Epizyme (EPZM), Xencor (XNCR), Turning Point Therapeutics (TPTX), Eidos Therapeutics (EIDX), Ironwood Pharmaceuticals (IRWD), Ligand Pharmaceuticals (LGND), BELLUS Health (BLUSF), Tricida (TCDA) and Arvinas (ARVN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include Arbutus Biopharma (ABUS), Axsome Therapeutics (AXSM), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), Aurinia Pharmaceuticals (AUPH), Cidara Therapeutics (CDTX), Concert Pharmaceuticals (CNCE), Corbus Pharmaceuticals (CRBP), Crispr Therapeutics (CRSP) and CytomX Therapeutics (CTMX).

(CRNX) raised $80 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray acted as the underwriters for the IPO.

Crinetics Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), 5AM Venture Management LLC (9.75%), Janus Henderson Group PLC (2.02%), State Street Corp (0.94%), Victory Capital Management Inc. (0.81%) and Victory Capital Management Inc. (0.79%). Company insiders that own Crinetics Pharmaceuticals stock include Alan Seth Krasner, Life Sciences Maste Perceptive, Matthew K Fust, Ventures Iv LP 5Am, Vivo Capital Fund Viii, LP and Vivo Capital Viii, Llc. View Institutional Ownership Trends for Crinetics Pharmaceuticals.

CRNX stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Victory Capital Management Inc., Victory Capital Management Inc. and Janus Henderson Group PLC. Company insiders that have sold Crinetics Pharmaceuticals company stock in the last year include Matthew K Fust, Ventures Iv LP 5Am, Vivo Capital Fund Viii, LP and Vivo Capital Viii, Llc. View Insider Buying and Selling for Crinetics Pharmaceuticals.

CRNX stock was purchased by a variety of institutional investors in the last quarter, including 5AM Venture Management LLC, State Street Corp, California Public Employees Retirement System, UBS Group AG, FMR LLC, Geode Capital Management LLC, Barclays PLC and Rockefeller Capital Management L.P.. Company insiders that have bought Crinetics Pharmaceuticals stock in the last two years include Alan Seth Krasner, Life Sciences Maste Perceptive and Vivo Capital Viii, Llc. View Insider Buying and Selling for Crinetics Pharmaceuticals.

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CRNX stock can currently be purchased for approximately $21.08.

Crinetics Pharmaceuticals has a market capitalization of $510.60 million and generates $2.43 million in revenue each year. The company earns $-27,110,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Crinetics Pharmaceuticals employs 47 workers across the globe.View Additional Information About Crinetics Pharmaceuticals.

The official website for Crinetics Pharmaceuticals is http://www.crinetics.com/.

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at 858-450-6464 or via email at [email protected]